TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms

Turk J Haematol. 2017 Jun 5;34(2):174-178. doi: 10.4274/tjh.2016.0401. Epub 2017 Feb 20.

Abstract

We aimed to determine the genotype distribution, allele frequency, and prognostic impact of IDH1/2, TET2, and ASXL1 single nucleotide polymorphisms (SNPs) in myeloproliferative neoplasms (MPNs). TET2 (rs763480), ASXL1 (rs2208131), and IDH1 (rs11554137) variant homozygous genotype frequencies were found at rates of 1.5%, 9.2%, and 2.3%, respectively. No IDH2 SNP was identified. IDH1 and TET2 frequencies were 5% in essential thrombocythemia (ET) and 1.7% in ET and 5% in primary myelofibrosis (PMF), respectively. ASXL1 frequencies were 8.3%-10% in MPN subgroups. The TET2 mutant allele T and ASXL1 mutant allele G had the highest frequencies with 0.272 in the PMF and 0.322 in the polycythemia vera (PV) group, respectively. There was no impact of the SNPs on prognosis. IDH1 frequency in MPNs was found similar to the literature. ASXL1 frequencies were similar between ET, PV, and PMF patients. The ASXL1 and TET2 allele frequencies of the Turkish population are similar to those of the European population. The role of SNPs in MPNs might be further evaluated in larger multicenter studies.

Bu çalışmada biz ASXL1, TET2, IDH1/2 genlerindeki tek nükleotid polimorifizmlerin (SNP) alel sıklığını, genotipik dağılımını ve prognostik etkisini saptamayı amaçladık. TET2 (rs763480), ASXL1 (rs2208131) ve IDH1 (rs11554137) varyant homozigot genotip sıklığı sırasıyla %1,5, %9,2 ve %2,3 saptandı. IDH2 SNP saptanmadı. IDH1 sıklığı ET’de %5 ve TET2 sıklığı ET’de %1,7 ve PMF’te %5 idi. ASXL1 sıklığı ise MPN alt gruplarında %8,3-10’du. En yüksek TET2 mutant allel T ve ASXL mutant allel G sıklığı sırasıyla PMF’te 0,272 ve PV’de 0,322 olarak saptandı. SNP’lerin prognoz üzerine etkisi yoktu. MPN’de IDH1 sıklığı literatür ile uyumlu bulundu. ASXL1 sıklığı PV, PMF ve ET alt gruplarında benzerdi. Türklerde ASXL1 ve TET2 allel sıklığı Avrupalılar ile benzer saptandı. MPN’lerde SNP’lerin rolü, büyük ve çok merkezli çalışmalarda değerlendirilmelidir.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Chronic Disease
  • DNA-Binding Proteins / genetics*
  • Dioxygenases
  • Disease-Free Survival
  • Female
  • Humans
  • Isocitrate Dehydrogenase / genetics*
  • Male
  • Middle Aged
  • Myeloproliferative Disorders* / genetics
  • Myeloproliferative Disorders* / mortality
  • Polymorphism, Single Nucleotide*
  • Proto-Oncogene Proteins / genetics*
  • Repressor Proteins / genetics*
  • Survival Rate
  • Turkey / epidemiology

Substances

  • ASXL1 protein, human
  • DNA-Binding Proteins
  • Proto-Oncogene Proteins
  • Repressor Proteins
  • IDH2 protein, human
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • Dioxygenases
  • TET2 protein, human